Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy.
about
Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancerChimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and ProspectsRemodeling Components of the Tumor Microenvironment to Enhance Cancer TherapyCombining radiotherapy with sunitinib: lessons (to be) learnedA quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trialTwelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.The mechanisms of radioresistance in esophageal squamous cell carcinoma and current strategies in radiosensitivityTumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapyOlder age impacts radiotherapy-related outcomes in soft tissue sarcoma.Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.Spatial distribution of FoxP3+ and CD8+ tumour infiltrating T cells reflects their functional activity.Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy.Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.Should we be combining local tumor therapies with immunotherapies as standard?Immunomodulatory effects of radiation: what is next for cancer therapy?Immune Therapy for Sarcomas.Increasing radiation dose improves immunotherapy outcome and prolongation of tumor dormancy in a subgroup of mice treated for advanced intracerebral melanoma.Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors.Immunological mechanism of low-dose priming radiation resistance in walker-256 tumor model micePhotodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer.Cancer-Targeted Selenium Nanoparticles Sensitize Cancer Cells to Continuous γ Radiation to Achieve Synergetic Chemo-Radiotherapy.Post-irradiation viability and cytotoxicity of natural killer cells isolated from human peripheral blood using different methods.Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo.Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab.Pembrolizumab for the treatment of melanoma.Cancer Cell Death-Inducing Radiotherapy: Impact on Local Tumour Control, Tumour Cell Proliferation and Induction of Systemic Anti-tumour Immunity.Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy.Present and future of cancer immunotherapy: A tumor microenvironmental perspectiveImpact of curative radiotherapy on the immune status of patients with localized prostate cancer
P2860
Q26740288-8CF0DCDA-6BA9-4553-B3ED-78DBE0CA7305Q26753082-0D671CFD-531B-4CD8-A39C-9DBF2F16D61FQ26777144-A1B202DB-4893-475B-9C5A-D2640847E574Q26800587-EAFD819D-73A8-4E97-A974-FC0324B59393Q28088679-ACD9C2AA-C463-4223-86C8-E1DCAB4427B3Q30846001-55B16C8D-163F-43F8-87A7-F940D302EE65Q33571306-2E95CE16-9853-4BDF-AF4A-5BD10A460339Q33881490-4C3FF40E-3790-4FBB-8F80-45390AB1C613Q36680534-CCB5ABB3-CD20-44FB-9108-FBF6AD0CA35BQ37566921-7F8FF8D8-5EB8-4AAC-93AB-99C42BF93F85Q37645030-482CDD98-9F06-45C2-A1F7-072B62A1238EQ37714274-D763AA08-3693-4057-AC97-8CF2D4D6C800Q38549542-92E5378F-3D36-4E7B-B8D5-CAFA4DD420A4Q38638858-562CB4B6-E528-4486-80F6-5343EEB000C2Q38654155-F9FADF1E-71F0-49E2-A5FD-023F75FFF158Q38742533-1FE8398D-7147-4C62-A55E-A9CAC87DA72FQ38812183-4D1F7891-4EEC-4482-8B16-FB5FABBE4DABQ39208496-C17011E2-9E43-409F-9A34-308D7FE45D61Q42376311-260DEA83-3EB9-41FB-9AE4-5A8009C62C94Q42958489-5E16190D-5C2A-446B-8F46-459E19B8217EQ46309055-FA85286B-0FA4-497E-B66F-D9CB41B5640BQ50206677-41675148-25F9-43E1-BA09-C9830ADB3B0FQ50544077-583323BC-6535-48DF-99C3-50CA22AD9A96Q50731156-EECC2878-93F9-4B85-BBCA-CF5C8D1E734AQ50957132-1D93404E-7C79-4185-9B95-5191AE6FB626Q51551651-ECAD864C-8B12-4134-866C-9CECE8645106Q55224585-0535A050-F8FC-4D9E-8C7E-716B762203ACQ55233806-27B0FDAF-304F-4B21-BC48-39D442D3D593Q57144510-CAA84B79-9DFE-4E4C-9950-54BAC40792B8Q58564319-9043505A-858C-428F-B47B-C4F5BE2A1574
P2860
Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Immune-priming of the tumor mi ...... o improve anticancer efficacy.
@en
type
label
Immune-priming of the tumor mi ...... o improve anticancer efficacy.
@en
prefLabel
Immune-priming of the tumor mi ...... o improve anticancer efficacy.
@en
P2093
P1476
Immune-priming of the tumor mi ...... o improve anticancer efficacy.
@en
P2093
David Tuck
Jedd D Wolchok
Michael A Postow
Vafa Shahabi
P356
10.1097/COC.0B013E3182868EC8
P577
2015-02-01T00:00:00Z